EDB fibronectin specific peptide for prostate cancer targeting

Bioconjugate Chemistry

Volumn 26, Issue 5, 2015, Pages 830-838

  Han, Zheng ^a   Zhou, Zhuxian ^a   Shi, Xiaoyue ^a   Wang, Junpeng ^a   Wu, Xiaohui ^a   Sun, Da ^a   Chen, Yinghua ^b   Zhu, Hui ^c   Magi Galluzzi, Cristina ^c   Lu, Zheng Rong ^a  

^a Case Western Reserve University   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION; DISEASES; MOLECULAR IMAGING; TUMORS; UROLOGY;

BIOLOGICAL PROCESS; CANCER-TARGETING; CELL MIGRATION; CELLS ADHESION; EPITHELIAL TO MESENCHYMAL TRANSITIONS; HIGH MOLECULAR WEIGHT; ISOFORMS; PROSTATE CANCERS; PROSTATE TUMOR; TUMORIGENESIS;

PEPTIDES;

EXTRADOMAIN B FIBRONECTIN; FIBRONECTIN; FLUORESCENT DYE; NONAPEPTIDE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; CARBOCYANINE; COLORING AGENT; CYANINE DYE 5; OLIGOPEPTIDE; ONCOFETAL FIBRONECTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN TARGETING; TUMOR XENOGRAFT; UPREGULATION; AMINO ACID SEQUENCE; ANIMAL; CELL TRANSFORMATION; CHEMISTRY; ENZYME SPECIFICITY; FLUORESCENCE IMAGING; METABOLISM; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; SECRETION (PROCESS); TUMOR CELL LINE;

MUS MUSCULUS;

AMINO ACID SEQUENCE; ANIMALS; CARBOCYANINES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COLORING AGENTS; FIBRONECTINS; HUMANS; MALE; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; OLIGOPEPTIDES; OPTICAL IMAGING; PROSTATIC NEOPLASMS; SUBSTRATE SPECIFICITY; TRANSFORMING GROWTH FACTOR BETA;

EID: 84930207080     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/acs.bioconjchem.5b00178     Document Type: Article

References (32)

1. Siegel, R., Naishadham, D., and Jemal, A. (2012) Cancer statistics, 2012 Ca-Cancer J. Clin. 62, 10-29
2. Barry, M. J. (2001) Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer N. Engl. J. Med. 344, 1373-7
3. Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., and Chinnaiyan, A. M. (2001) Delineation of prognostic biomarkers in prostate cancer Nature 412, 822-6
4. Melnikow, J., LeFevre, M., Wilt, T. J., and Moyer, V. A. Counterpoint: Randomized trials provide the strongest evidence for clinical guidelines: The US Preventive Services Task Force and Prostate Cancer Screening. Med. Care 51, 301-3.
5. Moyer, V. A. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Int. Med. 157, 120-34.
6. Wernert, N. (1997) The multiple roles of tumour stroma Virchows Arch. 430, 433-43
7. Park, J. and Schwarzbauer, J. E. (2014) Mammary epithelial cell interactions with fibronectin stimulate epithelial-mesenchymal transition Oncogene 33, 1649-57
8. Alisson-Silva, F., Freire-de-Lima, L., Donadio, J. L., Lucena, M. C., Penha, L., Sa-Diniz, J. N., Dias, W. B., and Todeschini, A. R. (2013) Increase of O-glycosylated oncofetal fibronectin in high glucose-induced epithelial-mesenchymal transition of cultured human epithelial cells PLoS One 8, e60471
9. Borsi, L., Carnemolla, B., Neri, D., and Zardi, L. (2001) Use of human recombinant antibodies to the marker of angiogenesis ED-B in cancer therapy Tumori 87, S8-S10
10. Hajitou, A., Pasqualini, R., and Arap, W. (2006) Vascular targeting: recent advances and therapeutic perspectives Trends Cardiovasc. Med. 16, 80-8
11. Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., and Shipitsin, M. 2008, The epithelial-mesenchymal transition generates cells with properties of stem cells Cell 133, 704-15
12. Balanis, N., Wendt, M. K., Schiemann, B. J., Wang, Z., Schiemann, W. P., and Carlin, C. R. (2013) Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway J. Biol. Chem. 288, 17954-67
13. Kaspar, M., Zardi, L., and Neri, D. (2006) Fibronectin as target for tumor therapy Int. J. Cancer 118, 1331-9
14. Ratliff, T. L., Kavoussi, L. R., and Catalona, W. J. (1988) Role of fibronectin in intravesical BCG therapy for superficial bladder cancer J. Urol. 139, 410-4
15. Tuxhorn, J. A., Ayala, G. E., and Rowley, D. R. (2001) Reactive stroma in prostate cancer progression J. Urol. 166, 2472-83
16. Albrecht, M., Renneberg, H., Wennemuth, G., Moschler, O., Janssen, M., Aumuller, G., and Konrad, L. (1999) Fibronectin in human prostatic cells in vivo and in vitro: expression, distribution, and pathological significance Histochem. Cell Biol. 112, 51-61
17. Freire-de-Lima, L., Gelfenbeyn, K., Ding, Y., Mandel, U., Clausen, H., Handa, K., and Hakomori, S. I. (2011) Involvement of O-glycosylation defining oncofetal fibronectin in epithelial-mesenchymal transition process Proc. Natl. Acad. Sci. U. S. A. 108, 17690-5
18. Suer, S., Sonmez, H., Karaaslan, I., Baloglu, H., and Kokoglu, E. (1996) Tissue sialic acid and fibronectin levels in human prostatic cancer Cancer Lett. 99, 135-7
19. Sonmez, H., Suer, S., Karaarslan, I., Baloglu, H., and Kokoglu, E. (1995) Tissue fibronectin levels of human prostatic cancer, as a tumor marker Cancer Biochem. Biophys. 15, 107-110
20. Inufusa, H., Nakamura, M., Adachi, T., Nakatani, Y., Shindo, K., Yasutomi, M., and Matsuura, H. (1995) Localization of oncofetal and normal fibronectin in colorectal cancer. Correlation with histologic grade, liver metastasis, and prognosis Cancer 75, 2802-8
21. Menzin, A. W., Loret de Mola, J. R., Bilker, W. B., Wheeler, J. E., Rubin, S. C., and Feinberg, R. F. (1998) Identification of oncofetal fibronectin in patients with advanced epithelial ovarian cancer: detection in ascitic fluid and localization to primary sites and metastatic implants Cancer 82, 152-8
22. Barron, D. A. and Rowley, D. R. (2012) The reactive stroma microenvironment and prostate cancer progression Endocr. Relat. Cancer 19, R187-204
23. Jaggi, M., Nazemi, T., Abrahams, N. A., Baker, J. J., Galich, A., Smith, L. M., and Balaji, K. C. (2006) N-cadherin switching occurs in high Gleason grade prostate cancer Prostate 66, 193-9
24. Wilkinson, K. D. (2004) Quantitative analysis of protein-protein interactions, in Protein-Protein Interactions, pp 15-31, Springer.
25. Jankovic, M. M. and Kosanovic, M. M. (2008) Fibronectin pattern in benign hyperplasia and cancer of the prostate Dis. Markers 25, 49-58
26. Glass, A. S., Cary, K. C., and Cooperberg, M. R. (2013) Risk-based prostate cancer screening: who and how? Curr. Urol. Rep. 14, 192-198
27. Locher, R., Erba, P. A., Hirsch, B., Bombardieri, E., Giovannoni, L., Neri, D., Durkop, H., and Menssen, H. D. (2014) Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of (131)I-L19SIP in a prostate cancer patient J. Cancer Res. Clin. Oncol. 140, 35-43
28. Wu, X., Yu, G., Lindner, D., Brady-Kalnay, S. M., Zhang, Q., and Lu, Z. R. (2014) Peptide targeted high-resolution molecular imaging of prostate cancer with MRI Am. J. Nucl. Med. Mol. Imaging 4, 525-36
29. Wu, X., Burden-Gulley, S. M., Yu, G. P., Tan, M., Lindner, D., Brady-Kalnay, S. M., and Lu, Z. R. Synthesis and evaluation of a peptide targeted small molecular Gd-DOTA monoamide conjugate for MR molecular imaging of prostate cancer. Bioconjugate Chem. 23, 1548-56.
30. Vahrmeijer, A. L., Hutteman, M., van der Vorst, J. R., van de Velde, C. J., and Frangioni, J. V. (2013) Image-guided cancer surgery using near-infrared fluorescence Nat. Rev. Clin. Oncol. 10, 507-18
31. Tan, M., Burden-Gulley, S. M., Li, W., Wu, X., Lindner, D., Brady-Kalnay, S. M., Gulani, V., and Lu, Z.-R. (2012) MR molecular imaging of prostate cancer with a peptide-targeted contrast agent in a mouse orthotopic prostate cancer model Pharm. Res. 29, 953-960
32. Schmittgen, T. D. and Livak, K. J. (2008) Analyzing real-time PCR data by the comparative CT method Nat. Protoc. 3, 1101-1108